Mark Lampert‘s Biotechnology Value Fund recently filed a Form 13G with the SEC, in which it reported acquiring 4.58 million shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH), which amass 9.99% of the company’s outstanding stock. The acquisition represents a new addition to Biotechnology Value Fund’s portfolio.
Anthera Pharmaceuticals is a biopharmaceutical company engaged in discovering and producing a variety of therapeutics to treat severe disorders. The company has two product candidates in development, and it recently reported a positive DSMB review from its Phase 3 SOLUTION Study of Sollupra™. Since the beginning of the year, the company’s stock has lost 34.05%.
bogdanhoda/Shutterstock.com
Out of the 749 hedge funds followed by Insider Monkey which filed 13Fs for the June 30 reporting period, nine investors were long Anthera Pharmaceuticals (NASDAQ:ANTH) at the end of the June quarter, down by one from the previous quarter. Some of the bullish investors contained Joseph Edelman’s Perceptive Advisors, which held a position worth $4.61 million, Kevin Kotler’s Broadfin Capital, with a position valued at $3.57 million, Kris Jenner, Gordon Bussard, Graham Mcphail’s Rock Springs Capital Management, Charles Davidson’s Wexford Capital, and Hal Mintz’ Sabby Capital.
An investor who dumped Anthera Pharmaceuticals (NASDAQ:ANTH) during the quarter was Howard Guberman’s Gruss Asset Management, which sold a position valued, at the end of March, at $2.56 million.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Biotechnology Value Trading Fund OS | 0 | 0 | 0 | 0 | 0 | 0% |
| BVF Partners OS Ltd | 0 | 0 | 0 | 0 | 0 | 0% |
| BVF Partners | 0 | 4,582,033 | 0 | 4,582,033 | 4,582,033 | 9.99% |
| BVF Inc | 0 | 4,582,033 | 0 | 4,582,033 | 4,582,033 | 9.99% |
| Mark N. Lampert | 0 | 4,582,033 | 0 | 4,582,033 | 4,582,033 | 9.99% |
Page 1 of 14 – SEC Filing
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
| Anthera Pharmaceuticals, Inc. |
| (Name of Issuer) |
| Common Stock, $0.001 par value |
| (Title of Class of Securities) |
| 03674U 20 1 |
| (CUSIP Number) |
| September 6, 2016 |
| (Date of Event Which Requires Filing of this Statement) |
| o | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| o | Rule 13d-1(d) |
_______________
